Shares of Teladoc Health Inc.
rallied about 9% in trading on Monday after the company said in a securities filing that it narrowed revenue guidance for 2022 to $2.403 billion to $2.410 billion, from $2.395 billion to $2.410 billion, matching the FactSet consensus of $2.400 billion in sales for the year. William Blair analysts said the narrowed guidance is a “positive announcement.” Teladoc plans to share additional information about its fiscal performance during a presentation on Monday morning at the annual J.P. Morgan Healthcare Conference. Teladoc’s stock is down 3.3% over the past three months, while the broader S&P 500
is up 4.0%.